📊 BGMSP Key Takeaways
Is Bio Green Med Solution, Inc. (BGMSP) a Good Investment?
Bio Green Med Solution is a pre-revenue pharmaceutical company burning significant cash with minimal commercial traction. With only $81K in revenue against $7.3M in operating losses and negative free cash flow of $4.7M, the company is consuming its cash reserves at an unsustainable rate. At current burn rates, the $3.8M cash position provides less than 10 months of runway.
Bio Green Med Solution, Inc. shows extremely weak fundamentals, with only $81K of revenue against $7.34M of operating loss and $4.74M of negative free cash flow. While the balance sheet is currently liquid and lightly levered, the business has not demonstrated viable operating scale, sustainable margins, or acceptable growth quality.
Why Buy Bio Green Med Solution, Inc. Stock? BGMSP Key Strengths
- Minimal debt burden with Debt/Equity ratio of 0.00x
- Adequate liquidity ratios (Current Ratio 6.43x, Quick Ratio 5.07x) in the near term
- Total assets of $8.2M provide some balance sheet cushion
- Strong liquidity with a 6.43x current ratio and $3.84M in cash
- Minimal leverage with effectively no long-term debt and 0.00x debt-to-equity
- Positive equity base of $7.10M provides some near-term balance sheet support
BGMSP Stock Risks: Bio Green Med Solution, Inc. Investment Risks
- Critically low revenue of $81K with operating losses of $7.3M indicating failed commercialization or product-market fit
- Negative free cash flow of $4.7M annually will deplete $3.8M cash reserves within 10 months without additional funding
- Extreme profitability deficits: Operating Margin of -9067.9% and Net Margin of -2946.9% indicate fundamental business model failure
- Zero insider filings in last 90 days suggests lack of confidence from management
- No clear path to profitability with massive operating losses relative to minimal revenue
- Revenue base is negligible relative to the cost structure, indicating a non-viable operating model at present
- Severe losses and deeply negative margins suggest weak business quality and poor earnings visibility
- Ongoing cash burn from operations raises the risk of future dilution or capital needs if revenue does not improve materially
Key Metrics to Watch
- Quarterly revenue trends and commercial milestones
- Monthly cash burn rate and remaining runway
- Operating loss trajectory and cost structure improvements
- Cash position and timeline for next funding requirement
- Revenue growth relative to operating expense growth
- Operating cash burn and ending cash balance
Bio Green Med Solution, Inc. (BGMSP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.43x current ratio provides a solid financial cushion.
BGMSP Profit Margin, ROE & Profitability Analysis
BGMSP vs Healthcare Sector: How Bio Green Med Solution, Inc. Compares
How Bio Green Med Solution, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bio Green Med Solution, Inc. Stock Overvalued? BGMSP Valuation Analysis 2026
Based on fundamental analysis, Bio Green Med Solution, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bio Green Med Solution, Inc. Balance Sheet: BGMSP Debt, Cash & Liquidity
BGMSP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bio Green Med Solution, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-502.46 indicates the company is currently unprofitable.
BGMSP Revenue Growth, EPS Growth & YoY Performance
BGMSP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.0K | -$81.0K | $-1.31 |
| Q2 2025 | $4.0K | -$81.0K | $-0.98 |
| Q1 2025 | $29.0K | -$81.0K | $0.00 |
| Q3 2024 | $10.0K | -$2.0M | N/A |
| Q1 2024 | N/A | -$2.9M | $-2.27 |
| Q3 2023 | N/A | -$4.1M | N/A |
| Q2 2023 | N/A | -$2.9M | $-0.44 |
| Q1 2023 | N/A | -$4.1M | $-0.42 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bio Green Med Solution, Inc. Dividends, Buybacks & Capital Allocation
BGMSP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bio Green Med Solution, Inc. (CIK: 0001130166)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BGMSP
What is the AI rating for BGMSP?
Bio Green Med Solution, Inc. (BGMSP) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BGMSP's key strengths?
Claude: Minimal debt burden with Debt/Equity ratio of 0.00x. Adequate liquidity ratios (Current Ratio 6.43x, Quick Ratio 5.07x) in the near term. ChatGPT: Strong liquidity with a 6.43x current ratio and $3.84M in cash. Minimal leverage with effectively no long-term debt and 0.00x debt-to-equity.
What are the risks of investing in BGMSP?
Claude: Critically low revenue of $81K with operating losses of $7.3M indicating failed commercialization or product-market fit. Negative free cash flow of $4.7M annually will deplete $3.8M cash reserves within 10 months without additional funding. ChatGPT: Revenue base is negligible relative to the cost structure, indicating a non-viable operating model at present. Severe losses and deeply negative margins suggest weak business quality and poor earnings visibility.
What is BGMSP's revenue and growth?
Bio Green Med Solution, Inc. reported revenue of $81.0K.
Does BGMSP pay dividends?
Bio Green Med Solution, Inc. does not currently pay dividends.
Where can I find BGMSP SEC filings?
Official SEC filings for Bio Green Med Solution, Inc. (CIK: 0001130166) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BGMSP's EPS?
Bio Green Med Solution, Inc. has a diluted EPS of $-2.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BGMSP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bio Green Med Solution, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BGMSP stock overvalued or undervalued?
Valuation metrics for BGMSP: ROE of -33.6% (sector avg: 15%), net margin of -2,946.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BGMSP stock in 2026?
Our dual AI analysis gives Bio Green Med Solution, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BGMSP's free cash flow?
Bio Green Med Solution, Inc.'s operating cash flow is $-4.7M, with capital expenditures of $0.0. FCF margin is -5,848.1%.
How does BGMSP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,946.9% (avg: 12%), ROE -33.6% (avg: 15%), current ratio 6.43 (avg: 2).